0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Implantable Ophthalmic Drugs Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-39W18740
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Implantable Ophthalmic Drugs Market Research Report 2025
BUY CHAPTERS

Global Implantable Ophthalmic Drugs Market Research Report 2025

Code: QYRE-Auto-39W18740
Report
January 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Implantable Ophthalmic Drugs Market Size

The global market for Implantable Ophthalmic Drugs was valued at US$ 1340 million in the year 2024 and is projected to reach a revised size of US$ 1943 million by 2031, growing at a CAGR of 5.0% during the forecast period.

Implantable Ophthalmic Drugs Market

Implantable Ophthalmic Drugs Market

Ophthalmic implantable drugs are an innovative technology in the field of ophthalmic treatment in recent years. They deliver drugs directly to the eyes through implanted drug delivery systems, thereby improving the efficiency of the drugs and reducing the patient's medication burden.
North American market for Implantable Ophthalmic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Implantable Ophthalmic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Implantable Ophthalmic Drugs include Allergan (Durysta, Ozurdex), Glaukos (Idose TR), Graybug Vision (OTX-ITC), Ocular Therapeutix (ReSure), Novartis (Visudyne), Eylea (Bayer, Regeneron), Bausch&Lomb (Retisert, Vitrasert), Alimera Sciences (Iluvien), Mati (Evolute), Roche (Vabysmo), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Implantable Ophthalmic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Implantable Ophthalmic Drugs.
The Implantable Ophthalmic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Implantable Ophthalmic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Implantable Ophthalmic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Implantable Ophthalmic Drugs Market Report

Report Metric Details
Report Name Implantable Ophthalmic Drugs Market
Accounted market size in year US$ 1340 million
Forecasted market size in 2031 US$ 1943 million
CAGR 5.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Home
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Allergan (Durysta, Ozurdex), Glaukos (Idose TR), Graybug Vision (OTX-ITC), Ocular Therapeutix (ReSure), Novartis (Visudyne), Eylea (Bayer, Regeneron), Bausch&Lomb (Retisert, Vitrasert), Alimera Sciences (Iluvien), Mati (Evolute), Roche (Vabysmo)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Implantable Ophthalmic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Implantable Ophthalmic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Implantable Ophthalmic Drugs Market growing?

Ans: The Implantable Ophthalmic Drugs Market witnessing a CAGR of 5.0% during the forecast period 2025-2031.

What is the Implantable Ophthalmic Drugs Market size in 2031?

Ans: The Implantable Ophthalmic Drugs Market size in 2031 will be US$ 1943 million.

Who are the main players in the Implantable Ophthalmic Drugs Market report?

Ans: The main players in the Implantable Ophthalmic Drugs Market are Allergan (Durysta, Ozurdex), Glaukos (Idose TR), Graybug Vision (OTX-ITC), Ocular Therapeutix (ReSure), Novartis (Visudyne), Eylea (Bayer, Regeneron), Bausch&Lomb (Retisert, Vitrasert), Alimera Sciences (Iluvien), Mati (Evolute), Roche (Vabysmo)

What are the Application segmentation covered in the Implantable Ophthalmic Drugs Market report?

Ans: The Applications covered in the Implantable Ophthalmic Drugs Market report are Hospital, Clinic, Home

What are the Type segmentation covered in the Implantable Ophthalmic Drugs Market report?

Ans: The Types covered in the Implantable Ophthalmic Drugs Market report are Vitreous Implant Type, Lacrimal Gland Implant Type, Micropump implantable type, Others

Recommended Reports

Ophthalmic Drug Markets

Ophthalmic Devices & Implants

Retinal and Glaucoma Treatments

1 Implantable Ophthalmic Drugs Market Overview
1.1 Product Definition
1.2 Implantable Ophthalmic Drugs by Type
1.2.1 Global Implantable Ophthalmic Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Vitreous Implant Type
1.2.3 Lacrimal Gland Implant Type
1.2.4 Micropump implantable type
1.2.5 Others
1.3 Implantable Ophthalmic Drugs by Application
1.3.1 Global Implantable Ophthalmic Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home
1.4 Global Implantable Ophthalmic Drugs Market Size Estimates and Forecasts
1.4.1 Global Implantable Ophthalmic Drugs Revenue 2020-2031
1.4.2 Global Implantable Ophthalmic Drugs Sales 2020-2031
1.4.3 Global Implantable Ophthalmic Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Implantable Ophthalmic Drugs Market Competition by Manufacturers
2.1 Global Implantable Ophthalmic Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Implantable Ophthalmic Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Implantable Ophthalmic Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Implantable Ophthalmic Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Implantable Ophthalmic Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Implantable Ophthalmic Drugs, Product Type & Application
2.7 Global Key Manufacturers of Implantable Ophthalmic Drugs, Date of Enter into This Industry
2.8 Global Implantable Ophthalmic Drugs Market Competitive Situation and Trends
2.8.1 Global Implantable Ophthalmic Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Implantable Ophthalmic Drugs Players Market Share by Revenue
2.8.3 Global Implantable Ophthalmic Drugs Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Implantable Ophthalmic Drugs Market Scenario by Region
3.1 Global Implantable Ophthalmic Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Implantable Ophthalmic Drugs Sales by Region: 2020-2031
3.2.1 Global Implantable Ophthalmic Drugs Sales by Region: 2020-2025
3.2.2 Global Implantable Ophthalmic Drugs Sales by Region: 2026-2031
3.3 Global Implantable Ophthalmic Drugs Revenue by Region: 2020-2031
3.3.1 Global Implantable Ophthalmic Drugs Revenue by Region: 2020-2025
3.3.2 Global Implantable Ophthalmic Drugs Revenue by Region: 2026-2031
3.4 North America Implantable Ophthalmic Drugs Market Facts & Figures by Country
3.4.1 North America Implantable Ophthalmic Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Implantable Ophthalmic Drugs Sales by Country (2020-2031)
3.4.3 North America Implantable Ophthalmic Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Implantable Ophthalmic Drugs Market Facts & Figures by Country
3.5.1 Europe Implantable Ophthalmic Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Implantable Ophthalmic Drugs Sales by Country (2020-2031)
3.5.3 Europe Implantable Ophthalmic Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Implantable Ophthalmic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Implantable Ophthalmic Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Implantable Ophthalmic Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Implantable Ophthalmic Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Implantable Ophthalmic Drugs Market Facts & Figures by Country
3.7.1 Latin America Implantable Ophthalmic Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Implantable Ophthalmic Drugs Sales by Country (2020-2031)
3.7.3 Latin America Implantable Ophthalmic Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Implantable Ophthalmic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Implantable Ophthalmic Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Implantable Ophthalmic Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Implantable Ophthalmic Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Implantable Ophthalmic Drugs Sales by Type (2020-2031)
4.1.1 Global Implantable Ophthalmic Drugs Sales by Type (2020-2025)
4.1.2 Global Implantable Ophthalmic Drugs Sales by Type (2026-2031)
4.1.3 Global Implantable Ophthalmic Drugs Sales Market Share by Type (2020-2031)
4.2 Global Implantable Ophthalmic Drugs Revenue by Type (2020-2031)
4.2.1 Global Implantable Ophthalmic Drugs Revenue by Type (2020-2025)
4.2.2 Global Implantable Ophthalmic Drugs Revenue by Type (2026-2031)
4.2.3 Global Implantable Ophthalmic Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Implantable Ophthalmic Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Implantable Ophthalmic Drugs Sales by Application (2020-2031)
5.1.1 Global Implantable Ophthalmic Drugs Sales by Application (2020-2025)
5.1.2 Global Implantable Ophthalmic Drugs Sales by Application (2026-2031)
5.1.3 Global Implantable Ophthalmic Drugs Sales Market Share by Application (2020-2031)
5.2 Global Implantable Ophthalmic Drugs Revenue by Application (2020-2031)
5.2.1 Global Implantable Ophthalmic Drugs Revenue by Application (2020-2025)
5.2.2 Global Implantable Ophthalmic Drugs Revenue by Application (2026-2031)
5.2.3 Global Implantable Ophthalmic Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Implantable Ophthalmic Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Allergan (Durysta, Ozurdex)
6.1.1 Allergan (Durysta, Ozurdex) Company Information
6.1.2 Allergan (Durysta, Ozurdex) Description and Business Overview
6.1.3 Allergan (Durysta, Ozurdex) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Allergan (Durysta, Ozurdex) Implantable Ophthalmic Drugs Product Portfolio
6.1.5 Allergan (Durysta, Ozurdex) Recent Developments/Updates
6.2 Glaukos (Idose TR)
6.2.1 Glaukos (Idose TR) Company Information
6.2.2 Glaukos (Idose TR) Description and Business Overview
6.2.3 Glaukos (Idose TR) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Glaukos (Idose TR) Implantable Ophthalmic Drugs Product Portfolio
6.2.5 Glaukos (Idose TR) Recent Developments/Updates
6.3 Graybug Vision (OTX-ITC)
6.3.1 Graybug Vision (OTX-ITC) Company Information
6.3.2 Graybug Vision (OTX-ITC) Description and Business Overview
6.3.3 Graybug Vision (OTX-ITC) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Graybug Vision (OTX-ITC) Implantable Ophthalmic Drugs Product Portfolio
6.3.5 Graybug Vision (OTX-ITC) Recent Developments/Updates
6.4 Ocular Therapeutix (ReSure)
6.4.1 Ocular Therapeutix (ReSure) Company Information
6.4.2 Ocular Therapeutix (ReSure) Description and Business Overview
6.4.3 Ocular Therapeutix (ReSure) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Ocular Therapeutix (ReSure) Implantable Ophthalmic Drugs Product Portfolio
6.4.5 Ocular Therapeutix (ReSure) Recent Developments/Updates
6.5 Novartis (Visudyne)
6.5.1 Novartis (Visudyne) Company Information
6.5.2 Novartis (Visudyne) Description and Business Overview
6.5.3 Novartis (Visudyne) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis (Visudyne) Implantable Ophthalmic Drugs Product Portfolio
6.5.5 Novartis (Visudyne) Recent Developments/Updates
6.6 Eylea (Bayer, Regeneron)
6.6.1 Eylea (Bayer, Regeneron) Company Information
6.6.2 Eylea (Bayer, Regeneron) Description and Business Overview
6.6.3 Eylea (Bayer, Regeneron) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Eylea (Bayer, Regeneron) Implantable Ophthalmic Drugs Product Portfolio
6.6.5 Eylea (Bayer, Regeneron) Recent Developments/Updates
6.7 Bausch&Lomb (Retisert, Vitrasert)
6.7.1 Bausch&Lomb (Retisert, Vitrasert) Company Information
6.7.2 Bausch&Lomb (Retisert, Vitrasert) Description and Business Overview
6.7.3 Bausch&Lomb (Retisert, Vitrasert) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bausch&Lomb (Retisert, Vitrasert) Implantable Ophthalmic Drugs Product Portfolio
6.7.5 Bausch&Lomb (Retisert, Vitrasert) Recent Developments/Updates
6.8 Alimera Sciences (Iluvien)
6.8.1 Alimera Sciences (Iluvien) Company Information
6.8.2 Alimera Sciences (Iluvien) Description and Business Overview
6.8.3 Alimera Sciences (Iluvien) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Alimera Sciences (Iluvien) Implantable Ophthalmic Drugs Product Portfolio
6.8.5 Alimera Sciences (Iluvien) Recent Developments/Updates
6.9 Mati (Evolute)
6.9.1 Mati (Evolute) Company Information
6.9.2 Mati (Evolute) Description and Business Overview
6.9.3 Mati (Evolute) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Mati (Evolute) Implantable Ophthalmic Drugs Product Portfolio
6.9.5 Mati (Evolute) Recent Developments/Updates
6.10 Roche (Vabysmo)
6.10.1 Roche (Vabysmo) Company Information
6.10.2 Roche (Vabysmo) Description and Business Overview
6.10.3 Roche (Vabysmo) Implantable Ophthalmic Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Roche (Vabysmo) Implantable Ophthalmic Drugs Product Portfolio
6.10.5 Roche (Vabysmo) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Implantable Ophthalmic Drugs Industry Chain Analysis
7.2 Implantable Ophthalmic Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Implantable Ophthalmic Drugs Production Mode & Process Analysis
7.4 Implantable Ophthalmic Drugs Sales and Marketing
7.4.1 Implantable Ophthalmic Drugs Sales Channels
7.4.2 Implantable Ophthalmic Drugs Distributors
7.5 Implantable Ophthalmic Drugs Customer Analysis
8 Implantable Ophthalmic Drugs Market Dynamics
8.1 Implantable Ophthalmic Drugs Industry Trends
8.2 Implantable Ophthalmic Drugs Market Drivers
8.3 Implantable Ophthalmic Drugs Market Challenges
8.4 Implantable Ophthalmic Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Implantable Ophthalmic Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Implantable Ophthalmic Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Implantable Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Implantable Ophthalmic Drugs Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global Implantable Ophthalmic Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Implantable Ophthalmic Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Implantable Ophthalmic Drugs Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Implantable Ophthalmic Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Implantable Ophthalmic Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Implantable Ophthalmic Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Implantable Ophthalmic Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Implantable Ophthalmic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Implantable Ophthalmic Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Implantable Ophthalmic Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Implantable Ophthalmic Drugs Sales by Region (2020-2025) & (K Dose)
 Table 18. Global Implantable Ophthalmic Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Implantable Ophthalmic Drugs Sales by Region (2026-2031) & (K Dose)
 Table 20. Global Implantable Ophthalmic Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Implantable Ophthalmic Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Implantable Ophthalmic Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Implantable Ophthalmic Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Implantable Ophthalmic Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Implantable Ophthalmic Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Implantable Ophthalmic Drugs Sales by Country (2020-2025) & (K Dose)
 Table 27. North America Implantable Ophthalmic Drugs Sales by Country (2026-2031) & (K Dose)
 Table 28. North America Implantable Ophthalmic Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Implantable Ophthalmic Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Implantable Ophthalmic Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Implantable Ophthalmic Drugs Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe Implantable Ophthalmic Drugs Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe Implantable Ophthalmic Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Implantable Ophthalmic Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Implantable Ophthalmic Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Implantable Ophthalmic Drugs Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific Implantable Ophthalmic Drugs Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific Implantable Ophthalmic Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Implantable Ophthalmic Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Implantable Ophthalmic Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Implantable Ophthalmic Drugs Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America Implantable Ophthalmic Drugs Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America Implantable Ophthalmic Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Implantable Ophthalmic Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Implantable Ophthalmic Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Implantable Ophthalmic Drugs Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa Implantable Ophthalmic Drugs Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa Implantable Ophthalmic Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Implantable Ophthalmic Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Implantable Ophthalmic Drugs Sales (K Dose) by Type (2020-2025)
 Table 51. Global Implantable Ophthalmic Drugs Sales (K Dose) by Type (2026-2031)
 Table 52. Global Implantable Ophthalmic Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Implantable Ophthalmic Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Implantable Ophthalmic Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Implantable Ophthalmic Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Type (2020-2025)
 Table 59. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Type (2026-2031)
 Table 60. Global Implantable Ophthalmic Drugs Sales (K Dose) by Application (2020-2025)
 Table 61. Global Implantable Ophthalmic Drugs Sales (K Dose) by Application (2026-2031)
 Table 62. Global Implantable Ophthalmic Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Implantable Ophthalmic Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Implantable Ophthalmic Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Implantable Ophthalmic Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Implantable Ophthalmic Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Application (2020-2025)
 Table 69. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Application (2026-2031)
 Table 70. Allergan (Durysta, Ozurdex) Company Information
 Table 71. Allergan (Durysta, Ozurdex) Description and Business Overview
 Table 72. Allergan (Durysta, Ozurdex) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. Allergan (Durysta, Ozurdex) Implantable Ophthalmic Drugs Product
 Table 74. Allergan (Durysta, Ozurdex) Recent Developments/Updates
 Table 75. Glaukos (Idose TR) Company Information
 Table 76. Glaukos (Idose TR) Description and Business Overview
 Table 77. Glaukos (Idose TR) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. Glaukos (Idose TR) Implantable Ophthalmic Drugs Product
 Table 79. Glaukos (Idose TR) Recent Developments/Updates
 Table 80. Graybug Vision (OTX-ITC) Company Information
 Table 81. Graybug Vision (OTX-ITC) Description and Business Overview
 Table 82. Graybug Vision (OTX-ITC) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. Graybug Vision (OTX-ITC) Implantable Ophthalmic Drugs Product
 Table 84. Graybug Vision (OTX-ITC) Recent Developments/Updates
 Table 85. Ocular Therapeutix (ReSure) Company Information
 Table 86. Ocular Therapeutix (ReSure) Description and Business Overview
 Table 87. Ocular Therapeutix (ReSure) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. Ocular Therapeutix (ReSure) Implantable Ophthalmic Drugs Product
 Table 89. Ocular Therapeutix (ReSure) Recent Developments/Updates
 Table 90. Novartis (Visudyne) Company Information
 Table 91. Novartis (Visudyne) Description and Business Overview
 Table 92. Novartis (Visudyne) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Novartis (Visudyne) Implantable Ophthalmic Drugs Product
 Table 94. Novartis (Visudyne) Recent Developments/Updates
 Table 95. Eylea (Bayer, Regeneron) Company Information
 Table 96. Eylea (Bayer, Regeneron) Description and Business Overview
 Table 97. Eylea (Bayer, Regeneron) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. Eylea (Bayer, Regeneron) Implantable Ophthalmic Drugs Product
 Table 99. Eylea (Bayer, Regeneron) Recent Developments/Updates
 Table 100. Bausch&Lomb (Retisert, Vitrasert) Company Information
 Table 101. Bausch&Lomb (Retisert, Vitrasert) Description and Business Overview
 Table 102. Bausch&Lomb (Retisert, Vitrasert) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. Bausch&Lomb (Retisert, Vitrasert) Implantable Ophthalmic Drugs Product
 Table 104. Bausch&Lomb (Retisert, Vitrasert) Recent Developments/Updates
 Table 105. Alimera Sciences (Iluvien) Company Information
 Table 106. Alimera Sciences (Iluvien) Description and Business Overview
 Table 107. Alimera Sciences (Iluvien) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Alimera Sciences (Iluvien) Implantable Ophthalmic Drugs Product
 Table 109. Alimera Sciences (Iluvien) Recent Developments/Updates
 Table 110. Mati (Evolute) Company Information
 Table 111. Mati (Evolute) Description and Business Overview
 Table 112. Mati (Evolute) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 113. Mati (Evolute) Implantable Ophthalmic Drugs Product
 Table 114. Mati (Evolute) Recent Developments/Updates
 Table 115. Roche (Vabysmo) Company Information
 Table 116. Roche (Vabysmo) Description and Business Overview
 Table 117. Roche (Vabysmo) Implantable Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 118. Roche (Vabysmo) Implantable Ophthalmic Drugs Product
 Table 119. Roche (Vabysmo) Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Implantable Ophthalmic Drugs Distributors List
 Table 123. Implantable Ophthalmic Drugs Customers List
 Table 124. Implantable Ophthalmic Drugs Market Trends
 Table 125. Implantable Ophthalmic Drugs Market Drivers
 Table 126. Implantable Ophthalmic Drugs Market Challenges
 Table 127. Implantable Ophthalmic Drugs Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Implantable Ophthalmic Drugs
 Figure 2. Global Implantable Ophthalmic Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Implantable Ophthalmic Drugs Market Share by Type: 2024 & 2031
 Figure 4. Vitreous Implant Type Product Picture
 Figure 5. Lacrimal Gland Implant Type Product Picture
 Figure 6. Micropump implantable type Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Implantable Ophthalmic Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Implantable Ophthalmic Drugs Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Home
 Figure 13. Global Implantable Ophthalmic Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Implantable Ophthalmic Drugs Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Implantable Ophthalmic Drugs Sales (2020-2031) & (K Dose)
 Figure 16. Global Implantable Ophthalmic Drugs Average Price (US$/Dose) & (2020-2031)
 Figure 17. Implantable Ophthalmic Drugs Report Years Considered
 Figure 18. Implantable Ophthalmic Drugs Sales Share by Manufacturers in 2024
 Figure 19. Global Implantable Ophthalmic Drugs Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Implantable Ophthalmic Drugs Players: Market Share by Revenue in Implantable Ophthalmic Drugs in 2024
 Figure 21. Implantable Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Implantable Ophthalmic Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Implantable Ophthalmic Drugs Sales Market Share by Country (2020-2031)
 Figure 24. North America Implantable Ophthalmic Drugs Revenue Market Share by Country (2020-2031)
 Figure 25. United States Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Implantable Ophthalmic Drugs Sales Market Share by Country (2020-2031)
 Figure 28. Europe Implantable Ophthalmic Drugs Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Implantable Ophthalmic Drugs Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Implantable Ophthalmic Drugs Revenue Market Share by Region (2020-2031)
 Figure 36. China Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Implantable Ophthalmic Drugs Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Implantable Ophthalmic Drugs Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Colombia Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Implantable Ophthalmic Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Implantable Ophthalmic Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Implantable Ophthalmic Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Implantable Ophthalmic Drugs by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Implantable Ophthalmic Drugs by Type (2020-2031)
 Figure 56. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Implantable Ophthalmic Drugs by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Implantable Ophthalmic Drugs by Application (2020-2031)
 Figure 59. Global Implantable Ophthalmic Drugs Price (US$/Dose) by Application (2020-2031)
 Figure 60. Implantable Ophthalmic Drugs Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19B19893
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30B3636
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3H1702
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13C3384
Wed Sep 10 00:00:00 UTC 2025

Add to Cart